Kenneth C. Anderson

Kenneth C. Anderson, MD is Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, and holds the Kraft Family Professorship of Medicine at Harvard Medical School. He is widely regarded as one of the founding architects of modern myeloma therapy, having led or co-led the preclinical and early clinical development of bortezomib — the first proteasome inhibitor approved for cancer — and the immunomodulatory drug (IMiD) class, including thalidomide, lenalidomide, and pomalidomide. Dr. Anderson's laboratory was among the first to characterize how the bone marrow microenvironment — through direct cell-cell contact and paracrine cytokine signaling (IL-6, VEGF, IGF-1) — promotes myeloma cell survival, proliferation, and drug resistance. His preclinical studies in the 1990s demonstrating NF-κB pathway dependence in myeloma cell lines provided the rationale for proteasome inhibitor development in this disease. He collaborated extensively with Millennium Pharmaceuticals (now Takeda) to bring bortezomib through early clinical trials, culminating in its FDA approval in 2003 — the first new myeloma drug approval in over a decade and a paradigm shift that doubled median survival in myeloma over the following decade. Dr. Anderson has authored more than 1,000 peer-reviewed publications and holds numerous patents in oncology drug development.